Cytotoxicity and modes of action of five Cameroonian medicinal plants against multi-factorial drug resistance of tumor cells

A Review on Chemical Constituents and Biological Activities of the Genus <i>Beilschmiedia</i> (Lauraceae)

“…In addition, the leaves extract also displayed significant activity towards cell lines HCT116p53 (colon cancer cell), MDA-MB-231 (human breast carcinoma cell) and U87MG (human glioblastoma cell) with IC 50 of 4.79, 6.45, and 7.46 µg/mL, respectively. The bark extract also showed activity against the cell line MDA-MB-231 with an IC 50 value of 6.66 µg/mL [24].…”

“…Both in vivo and in vitro experiments have indicated that the Beilschmiedia plant extracts possess a variety of pharmacological aspects with antioxidant, anti-inflammatory, cytotoxicity, antibacterial and antifungal activities [23][24][25][26]. With consideration of the importance of the therapeutic property of this genus to heal various ailments.…”

Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells

“…The cytotoxicity of the tested samples was performed by resazurin reduction assay as previously described [19][20][21][22][23][24]. Briefly, adherent cells at 1×10 4 cells were allowed to attach overnight and then treated with different concentrations of the studied samples.…”

“…CCRF-CEM leukemia cells (1×10 6 ) were treated with the concentrations equivalent (eq.) to the IC 50 values of each and doxorubicin for 24, 48 and 72 h. Cells were measured after Vybrant® DyeCycle™ Violet staining (30 min at 37°C) on a LSR-Fortessa FACS analyzer (Becton-Dickinson, Germany) using the violet laser [20,23,24]. Cytographs were analyzed using FlowJo software (Celeza, Switzerland).…”

Comparative biological activities of extracts from three Malaysian Beilschmiedia species

“…B. erythrophloia and B. tsangii also displayed potent inhibition on anti-inflammatory activity (12). Other species, such as B. erythrophloia and B. acuta, were also found as cytotoxic agents, hence potential to be developed for drugs of anti-cancer (13). Based on these findings, there is a need to investigate other Beilschmiedia species from other origins to further develop the standardized extracts for specific medicinal purposes in the future.…”